Mesoridazine is a phenothiazine antipsychotic belonging to the thioridazine-related class of antipsychotic agents. It acts primarily through dopamine receptor antagonism and has additional effects on other neurotransmitter receptors.
Mesoridazine was historically used in the management of schizophrenia and other psychotic disorders. Its clinical use has been discontinued or restricted in many markets because of significant cardiac safety concerns, particularly QT-interval prolongation and risk of serious ventricular arrhythmias.
Mesoridazine is a specialized CNS / antipsychotic pharmaceutical API relevant to pharmaceutical research and reference-standard applications. Due to its historical regulatory status and safety profile, its commercial use should be evaluated against current applicable regulations.
CAS Number: 5588-33-0
Molecular Formula: C21H26N2O2S2
Molecular Weight: 386.57 g/mol
Chemical Name: Mesoridazine
Drug Class: Phenothiazine Antipsychotic
Therapeutic Class: Antipsychotic
Therapeutic Area: Psychiatry / CNS
Molecule Type: Synthetic Small Molecule
Mesoridazine produces antipsychotic effects primarily through dopamine receptor antagonism, particularly at central dopamine receptors.
Its pharmacological activity also involves interactions with other neurotransmitter systems, contributing to its broader CNS effects.
Key pharmacological actions include:
Historically, Mesoridazine was associated with:
Mesoridazine is notable for its cardiac electrophysiological safety concerns. It can prolong the QT interval and has been associated with potentially serious ventricular arrhythmias, including torsades de pointes.
Because of these concerns, mesoridazine's marketed clinical use has been withdrawn or discontinued in several jurisdictions. Therefore, any API listing should clearly distinguish it from currently marketed antipsychotic APIs and should comply with applicable regulatory requirements.
Historically, Mesoridazine was available in oral pharmaceutical formulations, including tablets and oral liquid preparations.
Mesoridazine is generally handled as a solid pharmaceutical substance. Appearance, crystalline characteristics and other physical properties should be controlled according to the applicable API specification.
A controlled Mesoridazine API manufacturing process may involve:
Typical Mesoridazine API testing may include:
Store Mesoridazine API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive moisture, heat and direct light.
Mesoridazine is relevant to research involving:
Mesoridazine is a phenothiazine antipsychotic compound with CAS Number 5588-33-0, molecular formula C21H26N2O2S2, and molecular weight 386.57 g/mol. It was historically used as an antipsychotic but is particularly notable for cardiac safety concerns involving QT prolongation and ventricular arrhythmias.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |